Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells

Blood

Volumn 89, Issue 6, 1997, Pages 2098-2104

  Kaufmann, Scott H ^a   Svingen, Phyllis A ^b   Gore, Steven D ^b   Armstrong, Deborah K ^b   Cheng, Yung Chi ^b   Rowinsky, Eric K ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYL SULFOXIDE; DNA; DNA TOPOISOMERASE; TOPOTECAN;

ARTICLE; CELL ISOLATION; CONCENTRATION RESPONSE; COVALENT BOND; DNA ADDUCT; DNA PROTEIN COMPLEX; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; MICROFLUOROMETRY; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DNA INTERACTION;

EID: 0030933933     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.6.2098     Document Type: Article

References (35)

1. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85:271, 1993
2. Chen AY, Liu LF: DNA Topoisomerases: Essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34:191, 1994
3. Potmesil M: Camptothecins: From bench research to hospital wards. Cancer Res 54:1431, 1994
4. Pommeir Y, Leteurtre F, Fesen MR, Fujimori A, Bertrand R, Solary E, Kohlhagen G, Kohn KW: Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 12:530, 1994
5. Kaufmann SH: Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: A cautionary note. Cancer Res 49:5870, 1989
6. Uckun FM, Stewart CF, Reaman G, Chelstrom LM, Jin J, Chandan-Langlie M, Waddick KG, White J, Evans WE: In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells. Blood 85:2817, 1995
7. Rowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen T-L, Peereboom D, Bowling MK, Sartorius SE, Ettinger DS, Forastiere AA, Donehower RC: Sequences of topotecan and cisplatin: Phase I, pharmacologic and in vitro studies to examine sequence-dependence. J Clin Oncol 14:3074, 1996
8. Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating MJ, Estey EH: Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 81:1146, 1993
9. Rowinsky EK, Adjei AA, Donehower RC, Gore SD, Jones RJ, Burke PJ, Cheng Y-C, Grochow LB, Kaufmann SH: Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 12:2193, 1994
10. Rowinsky EK, Kaufmann SH, Baker SD, Miller CB, Sartorius SE, Bowling MK, Chen T-L, Donehower RC, Gore SD: A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia. Clin Cancer Res 2:1921, 1996
11. Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, Liu LF: Camptothecin overcomes mdrl-mediated resistance in human KB carcinoma cells. Cancer Res 51:6039, 1991
12. Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC, Kaufmann SH: Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 52:2268, 1992
13. Yang C-HJ, Horton JK, Cowan KH, Schneider E: Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res 55:4004, 1995
14. Sorensen M, Sehested M, Jensen PB: Characterization of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. Br J Cancer 72:399, 1995
15. Goldwasser F, Bae I, Valenti M, Torres K, Pommier Y: Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 55:2116, 1995
16. Tricoli JV, Kowalski D: Topoisomerase I from chicken erythrocytes: Purification, characterization, and detection by a deoxyribonucleic acid binding assay. Biochemistry 22:2025, 1983
17. Hsiang Y-H, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722, 1988
18. Zwelling LA, Hinds M, Chan D, Mayes J, Sie KL, Parker E, Silberman L, Radcliffe A, Beran M, Blick M: Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topuisomerase II. J Biol Chem 264:16411, 1989
19. Kaufmann SH, Charron M, Burke PJ, Karp JE: Changes in topoisomerase I levels and localization during myeloid maturation in vitro and in vivo. Cancer Res 55:1255, 1995
20. Chang J-Y, Dethlefsen LA, Barley LR, Zhou BS, Cheng Y-C: Characterization of camptothecin-resistant Chinese hamster lung cells. Biochem Pharmacol 43:2443, 1992
21. Boege F, Andersen A, Jensen S, Zeidler R, Kreipe H: Proliferation-associated nuclear antigen-Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies. Am J Pathol 146:1302, 1995
22. Lamarre D, Talbot B, deMurcia G, Laplante C, Leduc Y, Mazen A, Poirier GG: Structural and functional analysis of poly (ADP-ribose) polymerase: An immunological study. Biochim Biophys Acta 950:147, 1988
23. Fields AP, Kaufmann SH, Shaper JH: Analysis of the internal nuclear matrix. Oligomers of a 38 kD nucleolar polypeptide stabilized by disulfide bonds. Exp Cell Res 164:139, 1986
24. Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA, Cowan K, Wendel K, Burke PJ: Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 83:517, 1994
25. Gore SD, Weng L-J, Jones RJ, Cowan K, Zilcha M, Piantadosi S, Burke P: Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia. Clin Cancer Res 1:295, 1995
26. Kaufmann SH, Karp JE, Burke PJ, Gore SD: Addition of etoposide to initial therapy of adult ALL: A combined clinical and laboratory study. Leuk Lymphoma 23:71, 1996
27. Kaufmann SH, McLaughlin SJ, Kastan M, Liu LF, Karp JE, Burke PJ: Topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Res 51:3534, 1991
28. Tanford C, Pain RH, Otchin NS: Equilibrium and kinetics of the unfolding of lysozyme (muramidase) by guanidine hydrochloride. J Mol Biol 15:489, 1966
29. Tanford C, Kawahara K, Lapanje S: Proteins in 6-M guanidine hydrochloride. Demonstration of random coil behavior. J Biol Chem 241:1921, 1966
30. Buckwalter CA, Lin AH, Tanizawa A, Pommier YG, Cheng Y-C, Kaufmann SH: RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I. Cancer Res 56:1647, 1996
31. Desnoyers S, Kaufmann SH, Poirier GG: Alteration of the nucleolar localization of Poly(ADP-ribose) polymerase upon treatment with transcription inhibitors. Exp Cell Res 227:146, 1996
32. Beidler DR, Cheng Y-C: Camptothecin induction of a time-and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol Pharmacol 47:907, 1995
33. Subramanian D, Kraut E, Staubus A, Young DC, Muller MT: Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer Res 55:2097, 1995
34. Ellis AL, Nowak B, Plunkett W, Zwelling LA: Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent. Cancer Chemother Pharmacol 34:249, 1994
35. Froelich-Ammon SJ, Osheroff N: Topoisomerase poisons: Harnessing the dark side of enzyme mechanism. J Biol Chem 270:21429, 1995